News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website


EpiGenX Rounds Out Scientific Advisory Board with Nobel Laureate (Business Wire)...and is a leading expert in the field of methylation, including identifying non-random and tumor-specific methylation patterns in human malignancies.......Dr Costello is a member of the Brain Tumor Research Center at UCSF and has had his work featured in editorials published in Nature Genetics,...- May 09 11:26 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/010509/2446.html

Posted on: 05/09/2001

"Yahoo - EpiGenX Rounds Out Scientific Advisory Board with Nobel Laureate"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
^DJI
^IXIC
^SPC
^IIX
^PSE
10943.56
2171.68
1263.22
207.67
772.05
+76.58
+15.05
+7.68
+1.63
+9.75
delayed 20 mins - disclaimer

Wednesday May 9, 11:26 am Eastern Time

Press Release

EpiGenX Rounds Out Scientific Advisory Board with Nobel Laureate

Dr. Yuan-Tseh Lee Joins Fellow Scientists on Biotechnology Company Advisory Board

SANTA BARBARA, Calif.--(BW HealthWire)--May 7, 2001--EpiGenX Pharmaceuticals Inc., announced today that Dr. Yuan-Tseh Lee has joined a distinguished advisory board which has been assembled to guide the Company in the development of epigenetic-based diagnostics and therapies for cancer and infectious disease. The Scientific Advisory Board, composed of leading scientists in the biotechnology and academic community, will be instrumental in accelerating the development and commercialization of the company's technologies.

Dr. Yuan-Tseh Lee joins an elite group including Michael T. Bowers, Ph.D., Professor of Chemistry and Thomas C. Bruice, Ph.D., Professor of Chemistry and Biochemistry from University of California, Santa Barbara; Joseph F. Costello, Ph.D., on the faculty of University of California, San Francisco, Department of Neurological Surgery; Melvin Louis DePamphilis, Ph.D., Section Chief for the Eukaryotic DNA Replication and Gene Expression unit of the Molecular Growth Laboratory at the National Institute of Child Health and Human Development; as well as Jeffrey L. Ebersole, Ph.D., Professor of Oral Health Research and Director, Center for Oral Health Research, from University of Kentucky, College of Dentistry and Arthur D. Riggs, Ph.D., Associate Director of the Beckman Research Institute of the City of Hope National Medical Center.

EpiGenX's Scientific Advisory Board now features expertise covering cancer biology, infectious disease, bioorganic chemistry and mass spectrometry technologies. Epigenetic strategies entail developing the advanced understanding of gene regulation, and its manipulation in order to fight disease, particularly cancer and infections.

"We are extremely honored to have Dr. Lee join our advisory board," commented Larry Bymaster, President and Chief Executive Officer, EpiGenX. "He has unparalleled expertise in molecular beam technology and we are pleased that he has agreed to provide counsel to our team of scientists."

"Dr. Lee is universally recognized as a world leader in design and use of customized state-of-the-art instrumentation for chemical analysis," noted Alec Wodke, Director of Epigenomics, EpiGenX. "We look forward to his guidance in defining the technology directions for our High Throughput Epigenetic applications."

    EpiGenX Scientific Advisory Board is now composed of:

    Michael T. Bowers, Ph.D., a Professor of Chemistry at UCSB, and
    one of the world's leading scientists in the field of mass
    spectrometry has served for over 10 years as, Editor,
    International Journal of Mass Spectrometry and Ion Processes and
    serves as Associate Editor Journal of the American Chemical
    Society. Dr. Bowers his Ph.D. in 1966 from the University of
    Illinois. His Awards include: Nobel Laureate Signature Award of
    the American Chemical Society (1988); American Chemical Society
    Award for Outstanding Achievement in Mass Spectrometry (1996);
    Guggenheim Fellowship (1994); and UCSB Faculty Research Lecturer
    (1994). He is a Fellow of the American Physical Society and of the
    American Association for the Advancement of Science.

    Thomas C. Bruice, Ph.D., a Professor of Chemistry and Biochemistry
    at UCSB, was listed among the world's 50 most cited chemists for
    the period from 1984 to 1991. He has been elected a Member of the
    National Academy of Sciences (1974), a Fellow of the American
    Academy of Arts and Sciences and a Fellow of the AAAS (1989) as
    well as the Royal Society of Chemistry. His awards include: NIH
    Career Development (1979); Lifetime Investigator and MERIT Awards;
    Guggenheim Fellow (1979); UCSB Faculty Research Award (1970);
    American Chemical Society Arthur C. Cope Scholar Award (1987),
    Richard C. Tolman Medal (1979), Repligan Medal in Biochemistry
    (1987), Alfred Bader Medal in Bioorganic and Bioinorganic
    Chemistry (1988), and the James Flack Norris Award (1996) in
    physical organic chemistry.

    Joseph F. Costello, Ph.D., serves on the faculty at University of
    California, San Francisco, Department of Neurological Surgery, and
    is a leading expert in the field of methylation, including
    identifying non-random and tumor-specific methylation patterns in
    human malignancies. His awards include the James S. McDonnell
    Foundation 21st Century Scientist Award. Dr Costello is a member
    of the Brain Tumor Research Center at UCSF and has had his work
    featured in editorials published in Nature Genetics, Science, The
    Scientist and Wired Magazine. He serves as an ad hoc reviewer for
    Nature Genetics, Proceedings of the National Academy of Science,
    Cancer Research, and Genes Chromosomes & Cancer.

    Melvin Louis DePamphilis, Ph.D., is the Section Chief for the
    Eukaryotic DNA Replication and Gene Expression unit of the
    Molecular Growth Laboratory at the National Institute of Child
    Health and Human Development, Bethesda, MD. He previously served
    as a Laboratory Head and Full Member of the Roche Institute of
    Molecular Biology, an Adjunct Professor in the Department of
    Biological Sciences at Columbia University, and a Professor in the
    Department of Biological Chemistry at Harvard Medical School. Dr.
    DePamphilis is one of the country's leading experts in the
    initiation of DNA replication in mammalian chromosomes; gene
    expression at the beginning of mammalian development. He currently
    serves on the editorial board of the following journals: Molecular
    Reproduction and Development, Molecular Biology Reports, Gene
    Therapy & Molecular Biology, Cell Structure and Function and
    Molecular and Cellular Biology.

    Jeffrey L. Ebersole, Ph.D., is Professor of Oral Health Research
    and Director, Center for Oral Health Research, at University of
    Kentucky, College of Dentistry. Earlier in his career, he was
    Professor of Periodontics and Microbiology at The University of
    Texas Health Center and, in the mid-1980's, Associate Clinical
    Professor of Oral Biology and Pathophysiology at the Harvard
    School of Dental Medicine. Dr. Ebersole's research area is B cell
    biology and antibodies in secretory immunity and periodontal
    immunobiology. He has had NIH funding for over 25 years. His
    primary research emphasis is in the development, specificity and
    functional abilities of antibodies in the oral cavity.

    Yuan-Tseh Lee, Ph.D., a Nobel laureate in chemistry in 1986, is
    the current President of Academia Sinica, the highest research
    institute in Taiwan. In 1986, Lee shared the Nobel Prize in
    Chemistry with Dudley R. Herschbach and John C. Polanyi for
    helping to apply the technology and theory of physics to
    chemistry. In his research, Lee extended Herschbach's "crossed
    molecular beam technique" to analyze larger and more complex
    molecules. Dr. Lee received his doctorate from the University of
    California at Berkeley in 1965. His world-leading laboratory now
    contains seven very sophisticated molecular beam apparati, which
    were specially designed to pursue problems, associated with
    reaction dynamics, photochemical processes, and molecular
    spectroscopy. His awards include: Alfred P. Sloan Fellow (1969 -
    1971); Fellow, American Academy of Arts and Science (1975);
    Fellow, American Physical Society, (1976); John Simon Guggenheim
    Fellow (1976 - 1977); Member, National Academy of Sciences (1979);
    Member, Academia Sinica, Taiwan, China (1980); Ernest O. Lawrence
    Award, U.S. Department of Energy (1981); Peter Debye Award of
    Physical Chemistry, American Chemical Society (1986) and the
    National Medal of Science in 1986.

    Arthur D. Riggs, Ph.D., a noted molecular biologist, serves as the
    Chair, Division of Biology, and Associate Director of the Beckman
    Research Institute of the City of Hope National Medical Center,
    which has been designated a Comprehensive Cancer Center by NCI.
    Dr. Riggs' was one of the scientific founders of Genentech. He is
    a pioneer in developing an understanding of how methylation acts
    as an epigenetic control. Currently he is studying X chromosome
    inactivation and the biological roles of DNA methylation. Dr.
    Riggs' scientific achievements span three decades at City of Hope.

EpiGenX has accepted invitations to make presentations at two industry conferences this month. The company will be presenting at the Innovative Drug Development Conference in New York on May 8th and the C21 Biotech Convergence Conference in Monterey Bay, California on May 23rd.

EpiGenX Pharmaceuticals is pioneering the development of epigenetic-based diagnostics and therapies tailored to the needs of individual patients. Epigenetic strategies entail developing the advanced understanding of gene regulation, and its manipulation in order to fight disease, particularly cancer and infections. The company's technology platforms all involve DNA methylation. EpiGenX has three commercialization pathways. Its drug discovery tools, EpiHiTS(TM) Technology include a suite of high-throughput assays for the rapid discovery of new epigenetic-based drugs. The company is developing novel and safe therapeutics to fight cancer and infectious diseases through epigenetic mechanisms. EpiGenX is also developing a suite of high-throughput diagnostic and epigenomics technologies to generate information on the activity and inactivity of genes in relation to various diseases. EpiGenX Pharmaceuticals, Inc., is located in Santa Barbara, CA. For more information, call 805-964-4486 or log on to http://www.epigenx.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "expect," "intend to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties, and actual results could differ materially from those expressed in any forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, competitive factors, the ability to successfully complete additional financings and other risks.


Contact:
     EpiGenX Pharmaceuticals, Inc.
     Mark Wilkinson, 805/964-4486
     mark@epigenx.com
      or
     Larry O. Bymaster, 805/964-4486
     larry@epigenx.com
      or
     Ken Richards, 805/964-4486
     ken@epigenx.com

Email this story - Most-emailed articles - Most-viewed articles


Related News Categories: biotech, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740